Zhan et al. (Zhan et al., 2023) elucidated that METTL3 augments GLUT1 expression, thereby accelerating ccRCC progression and conferring resistance to mammalian target of rapamycin (mTOR) inhibitors. Here, METTL3 is linked to nonpapillary renal cell carcinoma.